<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>the akampioneer &#187; KRAS</title>
	<atom:link href="http://akampioneer.com/tag/kras/feed" rel="self" type="application/rss+xml" />
	<link>http://akampioneer.com</link>
	<description></description>
	<lastBuildDate>Thu, 02 Feb 2012 19:00:15 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.1</generator>
		<item>
		<title>Company News: Micromet&#8217;s BiTE Antibodies Overcome Cancer Cell Resistance</title>
		<link>http://akampioneer.com/company-news/company-news-micromets-bite-antibodies-overcome-cancer-cell-resistance.html</link>
		<comments>http://akampioneer.com/company-news/company-news-micromets-bite-antibodies-overcome-cancer-cell-resistance.html#comments</comments>
		<pubDate>Mon, 05 Jul 2010 07:17:03 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[antibodies]]></category>
		<category><![CDATA[BiTE]]></category>
		<category><![CDATA[BRAF]]></category>
		<category><![CDATA[cetuximab]]></category>
		<category><![CDATA[EGFR]]></category>
		<category><![CDATA[Erbitux]]></category>
		<category><![CDATA[KRAS]]></category>
		<category><![CDATA[life cycle management]]></category>
		<category><![CDATA[Micromet]]></category>
		<category><![CDATA[panitumumab]]></category>
		<category><![CDATA[PNAS]]></category>
		<category><![CDATA[tumor resistance]]></category>
		<category><![CDATA[Vectibix]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=451</guid>
		<description><![CDATA[In several clinical trials, antibody company Micromet has demonstrated outstanding efficacy and safety of its bispecific BiTE antibodies which come with two binding sites: one for a cancer target and a second one for a T cell. As a result, T cells are recruited and guided directly to the tumor cell, initiating cancer cell death [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-micromets-bite-antibodies-overcome-cancer-cell-resistance.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

